NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug attack on advanced lung cancer enters major trial
Disease control Recruiting nowThis study is testing whether adding an experimental drug called telisotuzumab adizutecan to an existing lung cancer drug (osimertinib) works better than the current standard treatment. It is for adults with a specific type of advanced lung cancer that has spread and has a partic…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug takes aim at Tough-to-Treat lung cancer mutation
Disease control Recruiting nowThis study is testing a new drug, BL-M07D1, against standard chemotherapy for people with advanced lung cancer that has a specific genetic change called a HER2 mutation. It aims to see if the new drug can better control the cancer and help patients live longer without their disea…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New Two-Drug attack on Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called BL-M07D1 works better when combined with an existing immunotherapy (pembrolizumab) for people with a specific type of advanced lung cancer that has too much HER2 protein. It will involve about 80 adults whose cancer has spread and c…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New biosimilar drug trial aims to offer more affordable lung cancer treatment
Disease control Recruiting nowThis study is testing whether a proposed biosimilar drug called MB12 works as well as the established drug Keytruda (pembrolizumab) for treating advanced non-squamous non-small cell lung cancer. Both drugs are given in combination with standard chemotherapy. The main goals are to…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for advanced lung cancer patients in global treatment trial
Disease control Recruiting nowThis global Phase 3 trial is testing whether a new drug called rilvegostomig works better than the standard drug pembrolizumab when both are combined with chemotherapy. It's for people with advanced non-small cell lung cancer that has spread and expresses a specific marker (PD-L1…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Researchers dig through medical records to map lung cancer treatment journeys
Knowledge-focused Recruiting nowThis study looks back at the medical records of 250 Brazilian patients with advanced non-squamous non-small cell lung cancer whose initial chemotherapy stopped working. The goal is to understand what treatments doctors actually use in real-world clinics after that point and how p…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 21:25 UTC